Probuphine patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US7736665 TITAN PHARMS Implantable polymeric device for sustained release of buprenorphine
Apr, 2024

(6 months from now)

Probuphine is owned by Titan Pharms.

Probuphine contains Buprenorphine Hydrochloride.

Probuphine has a total of 1 drug patent out of which 0 drug patents have expired.

Probuphine was authorised for market use on 26 May, 2016.

Probuphine is available in implant;implantation dosage forms.

Probuphine can be used as for opioid dependence.

The generics of Probuphine are possible to be released after 25 April, 2024.

Drugs and Companies using BUPRENORPHINE HYDROCHLORIDE ingredient

Market Authorisation Date: 26 May, 2016

Treatment: For opioid dependence


More Information on Dosage

PROBUPHINE family patents

Family Patents

900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight

Join them to stay ahead in capturing the next drug going generic